These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 11351260)

  • 1. Association of the shrinkage of uterine leiomyoma treated with GnRH agonist and deletion of long arm of chromosome 7.
    Takahashi K; Kawamura N; Tsujimura A; Ichimura T; Ito F; Ishiko O; Ogita S
    Int J Oncol; 2001 Jun; 18(6):1259-63. PubMed ID: 11351260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
    Takahashi K; Kawamura N; Ishiko O; Ogita S
    Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment.
    Ito F; Kawamura N; Ichimura T; Tsujimura A; Ishiko O; Ogita S
    Fertil Steril; 2001 Jan; 75(1):125-30. PubMed ID: 11163826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two discrete regions of deletion at 7q in uterine leiomyomas.
    Ishwad CS; Ferrell RE; Hanley K; Davare J; Meloni AM; Sandberg AA; Surti U
    Genes Chromosomes Cancer; 1997 Jul; 19(3):156-60. PubMed ID: 9218996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists.
    Cheng YM; Chou CY; Huang SC; Lin HC
    BJOG; 2001 Jan; 108(1):95-102. PubMed ID: 11213012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
    Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
    Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allelotype analysis of uterine leiomyoma: localization of a potential tumor suppressor gene to a 4-cM region of chromosome 7q.
    van der Heijden O; Chiu HC; Park TC; Takahashi H; LiVolsi VA; Risinger JI; Barrett JC; Berchuck A; Evans AC; Behbakht K; Menzin AW; Liu PC; Benjamin I; Morgan MA; King SA; Rubin SC; Boyd J
    Mol Carcinog; 1998 Dec; 23(4):243-7. PubMed ID: 9869453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
    Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
    Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allelotype of uterine leiomyomas.
    Mao X; Barfoot R; Hamoudi RA; Easton DF; Flanagan AM; Stratton MR
    Cancer Genet Cytogenet; 1999 Oct; 114(2):89-95. PubMed ID: 10549262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
    Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
    Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GnRH agonists before surgery for uterine leiomyomas. A review.
    Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
    J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and cytogenetic analysis of chromosome 7 in uterine leiomyomas.
    Ishwad CS; Ferrell RE; Davare J; Meloni AM; Sandberg AA; Surti U
    Genes Chromosomes Cancer; 1995 Sep; 14(1):51-5. PubMed ID: 8527384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas.
    Di Lieto A; De Falco M; Pollio F; Mansueto G; Salvatore G; Somma P; Ciociola F; De Rosa G; Staibano S
    J Soc Gynecol Investig; 2005 Feb; 12(2):123-8. PubMed ID: 15695108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microallelotyping defines novel regions of loss of heterozygosity in uterine leiomyomas.
    Canevari Rde A; Pontes A; Rogatto SR
    Mol Carcinog; 2005 Mar; 42(3):177-82. PubMed ID: 15605361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
    Cramer SF
    Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
    [No Abstract]   [Full Text] [Related]  

  • 16. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
    Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
    Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro.
    Chung YJ; Chae B; Kwak SH; Song JY; Lee AW; Jo HH; Lew YO; Kim JH; Kim MR
    Int J Med Sci; 2014; 11(3):276-81. PubMed ID: 24516352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent loss of heterozygosity for chromosome 10 in uterine leiomyosarcoma in contrast to leiomyoma.
    Quade BJ; Pinto AP; Howard DR; Peters WA; Crum CP
    Am J Pathol; 1999 Mar; 154(3):945-50. PubMed ID: 10079273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
    Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
    Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semiquantitative assessment of MR imaging in prediction of efficacy of gonadotropin-releasing hormone agonist for volume reduction of uterine leiomyoma: initial experience.
    Okuda S; Oshio K; Shinmoto H; Tanimoto A; Asada H; Fujii T; Yoshimura Y; Kuribayashi S
    Radiology; 2008 Sep; 248(3):917-24. PubMed ID: 18710984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.